## Supporting Information

# Base-promoted triple cleavage of CCl<sub>2</sub>Br: A direct one-pot synthesis of unsymmetrical oxalamide derivatives

Alageswaran Jayaram, <sup>a</sup> Vijay Thavasianandam Seenivasan, <sup>a</sup> Karthick Govindan, <sup>a</sup> Yu- Ming Liu, <sup>a</sup> Nian-Qi Chen, <sup>a</sup> Ting-Wei Yeh, <sup>a</sup> Gokulakannan Venkatachalam, <sup>a</sup> Chien-Hung Li, <sup>a</sup> Tsz-Fai Leung, <sup>d</sup> and Wei-Yu Lin <sup>a-c</sup> \*

[a] Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung 80708, Taiwan, ROC.

[b] Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan, ROC.

[c] Drug Development and Value Creation Research Centre, Kaohsiung Medical University, Taiwan, ROC.

[d] Department of Chemistry, National Sun Yat-sen University, Taiwan, ROC.

\*Corresponding author: Wei-Yu Lin, <a href="https://www.wylin@kmu.edu.tw">wylin@kmu.edu.tw</a>

### **Table of Contents**

1	General information	3
2	Table S1. Optimization for the reaction conditions	4-5
3	Table S2. Optimization for 2-bromo-2,2-dichloro-N-	5-6
	methylacetamide derivatives	
4	Scheme S1. Gram-scale synthesis and derivatization	6
5	Scheme S2. Mechanistic studies	6-8
6	Scheme S3. Control experiments	9
7	Scheme S4. Possible reaction mechanism for amine	10
8	Scheme S5. Possible reaction mechanism for formamide	10
9	Synthesis of starting materials (1a-s)	11
10	Experimental procedure 2-morpholino-2-oxo derivatives (3a-3p),	11
	amine derivatives (5a-5j)	
11	Experimental procedure formamide derivatives (5a, 5k – 5p):	12
12	Experimental procedure for bromodichloro- <i>N</i> -methyl derivatives (6a-r)	12
13	Gram-scale synthesis	12-13
14	Experimental procedure indoline-2,3-dione derivatives (3aa):	14
15	Scheme S6. Triple cleavage of CCl <sub>2</sub> Br in Continuous-flow method	14-15
16	Spectral characterization	16-31
17	Reference	32
18	<sup>1</sup> H and <sup>13</sup> C spectra	33-160

#### 1. General information

All chemicals were purchased from commercial providers (Sigma Aldrich, Alfa Aesar, TCI, and Matrix Scientific) and used directly without further purification unless otherwise noted. Well-cleaned and oven dried glassware was used for the experiments. The reaction was monitored by Thin Layer Chromatography (TLC), purchased as pre-coated with silica gel 60 F254 from Merck. Column chromatography was carried out using the silica gel 230-400 mesh (purchased from Merck) with a mixture of ethyl acetate/hexane or hexane as the eluent. <sup>1</sup>H NMR spectra were recorded on 400 MHz and 600 MHz, <sup>13</sup>C-NMR spectra were recorded on 100 MHz and 151 MHz, and Varian mercury, Mercury plus, Unity plus, Jeol, and VNMR spectrometer using CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub> as solvent. The spectra were recorded and presented in chemical shifts (ppm) with tetramethylsilane (TMS) used as an internal standard. Multiplicities were provided in s (singlet), d (doublet), t (triplet), q (quartet), bs (broad singlet), m (multiplet) and dd (doublet of doublet), dq (doublet of quartets), td (triplet of doublets), Coupling constants (*J*) were reported in Hz. All the compounds were characterized by ESI mass on Thermo Finnigan (TRACEGC- POLARISQ) and HRMS (HR-ESI and HR-EI mode) on the *J*MS-700 spectrometer. Melting points were determined using Fargo instruments.

# 2. Table S1. Optimization for the reaction conditions <sup>a-k</sup>



Entry	Morpholine (equiv.)	CBr <sub>4</sub> (equiv.)	Base (equiv.)	Solvent	Yield (%) <sup>b</sup>
1	2	1.5	LiOH (2)	DMSO	45
2	2	1.5	NaOH (2)	DMSO	73
3	2	1.5	$Na_2CO_3(2)$	DMSO	63
4	2	1.5	NaHCO <sub>3</sub> (2)	DMSO	47
5	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	90 (85) <sup>c</sup>
6	2	1.5	K <sub>2</sub> HPO <sub>4</sub> (2)	DMSO	6
7	2	1.5	TEA (2)	DMSO	NR
8	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (1.5)	DMSO	67
9	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (1.0)	DMSO	34
10	2	1.5	-	DMSO	11
11	2	-	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	10
12	2	1	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	50
13	2	2	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	89
14	1.5	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	64
15	2.5	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	78
16	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	17 <sup>d</sup>
17	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	H <sub>2</sub> O	NR
18	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	CH <sub>3</sub> CN	21
19	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	MeOH	25
20	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	EtOH	42
21	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	Acetone	NR
22	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	37 <sup>e</sup>
23	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	76 <sup>f</sup>
24	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	66 <sup>g</sup>
25	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	50 <sup>h</sup>
26	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	77 <sup>i</sup>
27	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	61 <sup>j</sup>
28	2	1.5	Cs <sub>2</sub> CO <sub>3</sub> (2)	DMSO	67 <sup>k</sup>

<sup>a</sup> The reactions were performed with **1a** (0.2 mmol scale), CBr<sub>4</sub> (equiv.), Base (equiv.), DMSO: H<sub>2</sub>O (1:0.2) 2mL, at 80 °C under open air for 12 h. <sup>b</sup> Yields were determined by <sup>1</sup>H NMR spectroscopy using 1,3,5- trimethoxybenzene as the internal standard, <sup>c</sup> isolated yield, <sup>d</sup> without H<sub>2</sub>O, <sup>e</sup> reaction was performed at room temperature, <sup>f</sup> 70 °C, <sup>g</sup> 90 °C, <sup>h</sup> 300 µL of H<sub>2</sub>O, <sup>i</sup> 500 µL of H<sub>2</sub>O, <sup>j</sup> reaction was performed under N<sub>2</sub> atmosphere, <sup>k</sup> reaction was performed under O<sub>2</sub> atmosphere; NR = no reaction.



3.	Table S2. Optimization for 2-bromo-2,2-dichloro- <i>N</i> -methylacetamide derivatives <sup>a-b</sup>
----	---

Entry	CBr4 (equiv.)	Base	solvent	Yield (%) <sup>b</sup>
1	1.5	LiOH	CH₃CN	87
2	1.5	NaOH	CH₃CN	95
3	1.5	K <sub>2</sub> CO <sub>3</sub>	CH₃CN	53
4	1.5	Cs <sub>2</sub> CO <sub>3</sub>	CH₃CN	98
5	1.5	Et <sub>3</sub> N	CH₃CN	28
6	1.5	-	CH₃CN	NR
7	1.5	Cs <sub>2</sub> CO <sub>3</sub> (1.5 equiv.)	CH₃CN	84
8	1.5	Cs <sub>2</sub> CO <sub>3</sub> (1.0 equiv.)	CH₃CN	79
9	1.5	Cs <sub>2</sub> CO <sub>3</sub> (0.5 equiv.)	CH₃CN	65
10	1.5	Cs <sub>2</sub> CO <sub>3</sub>	H <sub>2</sub> O	NR.
11	1.5	Cs <sub>2</sub> CO <sub>3</sub>	MeOH	52
12	1.5	Cs <sub>2</sub> CO <sub>3</sub>	ethyl acetate	89
13	1.5	Cs <sub>2</sub> CO <sub>3</sub>	toluene	trace
14	1.5	Cs <sub>2</sub> CO <sub>3</sub>	acetone	trace
15	1.5	Cs <sub>2</sub> CO <sub>3</sub>	DMSO	90
16	1.0	Cs <sub>2</sub> CO <sub>3</sub>	CH₃CN	87
17	0.5	Cs <sub>2</sub> CO <sub>3</sub>	CH₃CN	53
18	NBS	Cs <sub>2</sub> CO <sub>3</sub>	CH₃CN	20

<sup>a</sup> The reactions were performed with **1g** (0.20 mmol),  $CBr_4$  (1.5 equiv.), Base (2.0 equiv.) at room temperature under open air for 2 h, <sup>b</sup> Isolated yield. NR= no reaction.

#### 4. Scheme S1. Gram-scale synthesis and derivatization



#### a) Gram-scale synthesis

#### 5. Scheme S2. Mechanistic studies

#### i) Identification of intermediates



A 15 mL reaction tube was charged with (**6a**) (0.2 mmol, 1.0 equiv.), morpholin (**2a**), (0.4 mmol, 2.0 equiv.),  $CS_2CO_3$  (0.4 mmol, 2.0 equiv.) with DMSO:  $H_2O$  (1:0.2) (2 mL). The resulting mixture was stirred at 80 °C in the open-air atmosphere for about 30 minutes. Then 0.5 mL of the reaction

solution was added into the test bottle and diluted with 0.5 mL of MeOH. The samples were immediately monitored by LCMS to deretermine the intermediates I & II.



Figure S2. Intermediate II

### ii) O<sup>18</sup> isotope labeling experiments

The  $O^{18}$  labeling experiment was conducted with **1a** and **2a** under the standard conditions with  $H_2O^{18}$  and the HRMS of the isolated product **3a** indicated that the oxygen atoms in carbonyl originated from  $H_2O$ .



#### 6. Scheme S3. Control experiments



#### 7. Scheme S4. Possible reaction mechanism for amine



2,2-dichloro-*N*-phenylacetamide (**1a**) undergoes electrophilic bromination upon reaction with CBr<sub>4</sub> under basic conditions, leading to the formation of intermediate **6a**. Subsequently, the bromodichloroacetamide **6a** undergoes hydrolysis to generate intermediate **I**, which is further converted into intermediate **II** through the elimination of HCl. Finally, the reactive intermediate **II** with an amine in the presence of a base yields an oxalamide product (**3a**).

#### 8. Scheme S4. Possible reaction Mechanism for formamide



#### 9. Synthesis of starting materials (1a-s): 1



All the starting materials (**1a-s**) were synthesized on 3.0 mmol scale, according to the literature procedure, and obtained in 20% - 93% yield, unless otherwise noted. The <sup>1</sup>H-NMR spectra of known starting materials were matched with previous literature and the unknown starting materials were characterized.

# 10. Experimental procedure 2-morpholino-2-oxo derivatives (3a-3p), & amine derivatives (5a-5j):



A 15 mL reaction tube was charged with (**1a-s**) (0.2 mmol, 1.0 equiv.), CBr<sub>4</sub> (0.4 mmol, 1.5 equiv.), CS<sub>2</sub>CO<sub>3</sub> (0.4 mmol, 2.0 equiv.), amine (0.4 mmol, 2.0 equiv.), with DMSO: H<sub>2</sub>O (1:0.2) (2 mL). The resulting mixture was stirred at 80 °C in the open-air atmosphere for about 12 h. After the completion of the reaction, reaction mixture was diluted with 5 mL of water. The aqueous layer was extracted with Ethyl acetate ( $3 \times 10$  mL), and the combined organic layer was washed with brine solution ( $1 \times 5$  mL). The final organic layer was then dried over MgSO<sub>4</sub> and concentrated under reduced pressure to get the crude product. The obtained crude product was purified using column chromatography by eluting with ethyl acetate/hexane (3:7) to afford pure 2-morpholino-2-oxo derivatives (**3a-p**) up to 29-91% yields and pure amine derivatives (**5a-5j**) up to 55-81% yields.

#### 11. Experimental procedure formamide derivatives (5a, 5k – 5p):



A 15 mL reaction tube was charged with (**1a**, **1b**, **1d**, **1f**, **1g**) (0.2 mmol, 1.0 equiv.), CBr<sub>4</sub> (0.3 mmol, 1.5 equiv.), NaOH (0.8 mmol, 4.0 equiv.), formamides (1 mL) with H<sub>2</sub>O (500  $\mu$ L). The resulting mixture was stirred at 25-30 °C in the open-air atmosphere for about 12 h. After the completion of the reaction, reaction mixture was diluted with 5 mL of water. The aqueous layer was extracted with Ethyl acetate (3 × 10 mL), and the combined organic layer was washed with brine solution (1 × 5 mL). The final organic layer was then dried over MgSO<sub>4</sub> and concentrated under reduced pressure to get the crude product. The obtained crude product was purified using column chromatography by eluting with ethyl acetate/hexane (3:7) to afford pure oxalamide derivatives (**5a**, **5k-5p**) up to 41-88% yields

12. Experimental procedure for bromodichloro-N-methyl derivatives (6a-r):



A 15 mL reaction tube was charged with (**1a-r**) (0.2 mmol, 1.0 equiv.), CBr<sub>4</sub> (0.3 mmol, 1.5 equiv.), CS<sub>2</sub>CO<sub>3</sub> (0.4 mmol, 2.0 equiv.) with CH<sub>3</sub>CN (2 mL). The resulting mixture was stirred at 25-30 °C in the open-air atmosphere for about 2 h. After the completion of the reaction, reaction mixture was diluted with 5 mL of water. The aqueous layer was extracted with Ethyl acetate (3 × 10 mL), and the combined organic layer was washed with brine solution (1 × 5 mL). The final organic layer was then dried over MgSO<sub>4</sub> and concentrated under reduced pressure to get the crude product. The obtained crude product was purified using column chromatography by eluting with ethyl acetate/hexane (1:9) to afford pure 2-bromo-2,2-dichloro-*N*-methyl derivatives (**6a-r**) up to 18-98% yields.

#### 13. General procedure for Gram-scale synthesis

i) Experimental Procedure for Gram-Scale Synthesis of 2-morpholino-2-oxo-*N*-phenylacetamide (3a):



A 100 mL round-bottom flask was charged with (**1a**) (6.0 mmol, 1.0 equiv.), CBr<sub>4</sub> (9 mmol, 1.5 equiv.), CS<sub>2</sub>CO<sub>3</sub> (12 mmol, 2.0 equiv.) with DMSO: H<sub>2</sub>O (1:0.2) (60 mL). The resulting mixture was stirred at 80 °C in the open-air atmosphere for about 12 h. After the completion of the reaction, the reaction mixture was diluted with 100 mL of water. The aqueous layer was extracted with Ethyl acetate (3 × 100 mL), and the combined organic layer was washed with brine solution (1 × 100 mL). The final organic layer was then dried over MgSO<sub>4</sub> and concentrated under reduced pressure to get the crude product. The obtained crude product was purified using column chromatography by eluting with ethyl acetate/hexane (3:7) to afford pure 2-morpholino-2-oxo-N-phenylacetamide (**3a**) 87% yields.

# ii) Experimental Procedure for Gram-Scale Synthesis of 2-bromo-*N*-(4-bromophenyl)-2,2 dichloroacetamide (6g):



A 100 mL round-bottom flask was charged with (**1a**) (4 mmol, 1.0 equiv.),  $CBr_4$  (6 mmol, 1.5 equiv.),  $CS_2CO_3$  (8 mmol, 2.0 equiv.) with  $CH_3CN$  (40 mL). The resulting mixture was stirred at 25-30 °C in the open-air atmosphere for about 2 h. After the completion of the reaction, the reaction mixture was diluted with 100 mL of water. The aqueous layer was extracted with Ethyl acetate  $(3 \times 100 \text{ mL})$ , and the combined organic layer was washed with brine solution  $(1 \times 100 \text{ mL})$ . The final organic layer was then dried over MgSO<sub>4</sub> and concentrated under reduced pressure to get the crude product. The obtained crude product was purified using column chromatography by eluting with ethyl acetate/hexane (1:9) to afford pure 2-bromo-2,2-dichloro-*N*-methyl derivatives (**6g**) 92% yield.





A mixture of 2-morpholino-2-oxo-N-phenylacetamide **3a** (46.85 mg, 0.2 mmol), POCl<sub>3</sub> (5.0 ml) was stirred at room temperature for 5 min. Then, transfer the reaction liquid to 65 °C and stir overnight under argon. After disappearance of the reactant (monitored by TLC), the reaction liquid was poured into 20 ml ice water and extracted with ethyl acetate three times (3 × 25 mL). The organic layer was washed with water and saturated brine, dried over MgSO<sub>4</sub> and evaporation. The residue was purified by column chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the pure  $N^1$ ,  $N^1$ -dimethyl- $N^2$ -phenyloxalamide derivatives (**3aa**) as an orange solid.

#### 15. Scheme S6. Triple cleavage of CCl<sub>2</sub>Br in Continuous-flow method

i) Optimization for the reaction conditions



Entry	Flow rate (F1:F2: F3)	Temperature (T1 :X °C)	Conversion yield (%)	Reaction time
	μL min⁻¹			(min)
1	(20:20:20)	80	85	42
2	(20:25:20)	80	90	40
3	(30:35:30)	80	85	30
4	(40:45:40)	80	75	20
5	(30:35:30)	70	85	30
6	(30:35:30)	60	84	30
7	(30:35:30)	50	70	30

#### ii) General procedure



A microreactor system consist of two T-shaped micromixers (M1 and M2), two tubing reactors (R1 and R2) and three reagents delivering units P1 (inner diameter = 800  $\mu$ m, length L = 25 cm), P2 (inner diameter = 800  $\mu$ m, length L= 25 cm) and, P3 (inner diameter = 800  $\mu$ m, length L= 25 cm) were used. A solution of **1** (0.1 M in DMSO) and CBr<sub>4</sub> (0.15 M in DMSO) and a solution of Cs<sub>2</sub>CO<sub>3</sub> (0.2 M in H<sub>2</sub>O) was introduced to M1 (M1,  $\Phi$  = 500  $\mu$ m) by syringe pumps. The resulting solution was passed through R1 ( $\Phi$  = 0.8 mm, L= 200 cm) and was mixed with a solution of morpholine **2a** (0.4 M in DMSO) (flow rate: 30  $\mu$ L/min) at M2 ( $\Phi$ = 500  $\mu$ m). The resulting solution was passed through R2 ( $\Phi$ = 0.8 mm, L= 500 cm) at 80 °C. After a steady state was reached (after 1 min), the final product solution was collected for 15 minutes in vial. The reaction mixture was analyzed by GC with 85% conversion, the solution was removed by vacuum. The crude product was purified by column chromatography (Hexane/EtOAc,7/3, silica gel) and obtained **3a, 3b, and 3f** (84%- 91%).

#### 16. Spectral characterization:

2,2-dichloro-N-(4-ethyl phenyl) acetamide (1c): The title compound was synthesized according



to the general procedure and obtained as white solid (633.6 mg, 91%); mp. 148-150 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.15 (s, 1H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 6.04 (s, 1H), 2.64 (q, *J* = 8.0 Hz, 2H), 1.23 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.33, 142.53,

134.41, 129.15, 120.99, 67.50, 28.95, 16.18; HRMS (HR-EI) m/z:  $[M^+]$  calcd for  $C_{10}H_{12}Cl_2NO$  232.0296; Found 232.0285.

N-(4-bromophenyl)-2,2-dichloroacetamide (1g): The title compound was synthesized according



to the general procedure and obtained as white solid (704.5 mg, 83%); mp. 160-162 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.14 (s, 1H), 7.47 (q, *J* = 8.0 Hz, 4H), 6.04 (s, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.09, 135.64, 132.60, 122.12, 118.92, 67.06; HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd for C<sub>8</sub>H<sub>6</sub>BrCl<sub>2</sub>NO

280.9010; Found 280.9005

2,2-dichloro-N-(2-iodophenyl)acetamide (1i): The title compound was synthesized according to



the general procedure and obtained as white solid (781.9mg, 79%); mp. 165-167 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.63 (s, 1H), 8.19 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.83 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.41-7.37 (m, 1H), 6.95-6.91 (m, 1H), 6.61 (s, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.09, 139.27, 136.91, 129.57,

127.30, 121.91, 90.30, 67.14; HRMS (HR-ESI) m/z:  $[M+Na]^+$  calcd for  $C_8H_6Cl_2INONa$  351.8769; Found 351.8761

2,2-dichloro-N-(4-chloro-3-nitrophenyl) acetamide (1m): The title compound was synthesized



according to the general procedure and obtained as yellow solid (289.1 mg, 34%); mp. 134-136 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.31 (s, 1H), 8.22 (d, *J* = 4.0 Hz, 1H), 7.75 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 6.04 (s, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.56, 136.28, 132.94,

124.76, 123.65, 117.42, 66.82; HRMS (HR-EI) m/z:  $[M^+]$  calcd for  $C_8H_5Cl_3N_2O_3281.9366$ ; Found 281.9366.

2,2-dichloro-N-(quinolin-3-yl) acetamide (10): The title compound was synthesized according to



the general procedure and obtained as a pale-yellow solid (344.4 mg, 45%); mp. 163-165 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  11.10 (s, 1H), 8.87 (d, *J* = 4.0 Hz, 1H), 8.66 (d, *J* = 4.0 Hz, 1H), 7.94 (d, *J* = 8.0 Hz, 2H), 7.67-7.63 (m, 1H), 7.58-7.54 (m, 1H), 6.66 (s, 1H); <sup>13</sup>C-NMR (100 MHz,

DMSO- $d_6$ )  $\delta$  163.01, 145.19, 144.89, 131.79, 129.07, 129.03, 128.41, 127.96, 127.78, 124.18, 67.53. HRMS (HR-ESI) m/z: [M+H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>2</sub>O 255.0092; Found 255.0081.

N-(benzo[d]thiazol-2-yl)-2,2-dichloroacetamide (1p): The title compound was synthesized



according to the general procedure and obtained as yellow solid (642.4 mg, 82%); mp. 203-205 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  7.87-7.82 (m, 2H), 7.49 (td, *J* = 8.0 Hz, 4.0Hz, 1H), 7.38(td, *J* = 8.0 Hz, 1.6Hz, 1H), 6.19 (s, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.05, 157.87, 147.86, 132.42,

127.12, 125.16, 122.01, 121.46, 65.98. HRMS (HR-ESI) m/z:  $[M+H]^+$  calcd for C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>2</sub>OS 260.9656; Found 260.9649.

N-(1-benzylpyrrolidin-3-yl)-2,2-dichloroacetamide (1q): The title compound was synthesized



according to the general procedure and obtained as brown semi solid (215.3 mg, 25%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  7.27 (s, 5H), 5.86 (s, 1H), 4.44-4.37 (m, 1H), 3.64 (s, 2H), 2.98-2.94 (m, 1H), 2.71 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 2.58 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 2.36-2.23

(m, 12H), 1.75-1.66 (m, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.64, 137.16, 129.07, 128.64, 127.75, 66.54, 59.79, 59.65, 52.42, 49.52, 31.92; HRMS (HR-ESI) m/z: [M+H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>17</sub>Cl-<sub>2</sub>N<sub>2</sub>O 287.0718; Found 287.0710.

2,2-dichloro-N-(9,10-dioxo-9,10-dihydroanthracen-2-yl)acetamide (1r): The title compound



was synthesized according to the general procedure and obtained as brown solid (200.5 mg, 20%); mp. 268-270 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.28 (s, 1H), 8.90 (s, 1H), 8.19-8.14 (m, 3H), 7.92-7.87 (m, 2H), 7.65 (s, 1H), 7.06 (s, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  182.24, 181.69, 163.08, 153.43, 134.83, 134.53, 133.64, 133.47, 131.28, 131.08, 127.08, 126.96, 126.12, 119.54, 112.30, 67.07. HRMS (HR-EI) m/z: [M+Na]<sup>+</sup> calcd for C<sub>8</sub>H<sub>6</sub>BrCl<sub>2</sub>NONa 355.9857; Found 355.9849.

N-(2-(1H-indol-3-yl) ethyl)-2,2-dichloroacetamide (1s): The title compound was synthesized



according to the general procedure and obtained as white solid (756.5 mg, 93%); mp. 109-111 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.44 (s, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 8.0 Hz, 1H) 7.40 (t, *J* = 8.0 Hz, 1H), 7.32 (d, *J* = 16.0 Hz, 1H), 7.21-7.20 (m, 1H), 6.86 (s, 1H),

6.04 (s, 1H), 3.81 (dd, J = 12.0 Hz, 4.0 Hz, 2H), 3.21 (t, J = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  164.09, 136.38, 126.99, 122.34, 122.25, 119.52, 118.53, 111.97, 111.37, 66.46, 40.51, 24.76. HRMS (HR-ESI) m/z: [M+H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O 271.0405; Found 271.0398.

2-morpholino-2-oxo-N-phenylacetamide (3a):<sup>3</sup> The title compound was synthesized



according to the general procedure and obtained as white solid (39.8 mg, 85%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.49 (s, 1H), 7.58 (d, *J* = 8.0 Hz, 2H), 7.30 (t, *J* = 8.0 Hz, 2H), 7.11 (t, *J* = 8.0 Hz, 1H), 4.17 (t, *J* = 4.0 Hz, 2H), 3.71-3.65 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.59, 158.52,

136.80, 128.98, 125.08, 119.98, 67.05, 66.60, 47.17, 43.72.

2-morpholino-2-oxo-N-(p-tolyl)acetamide (3b):<sup>4</sup> The title compound was synthesized according



to the general procedure and obtained as white solid (41.7 mg, 84%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.20 (s, 1H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 4.30 (t, *J* = 8.0 Hz, 2H), 3.78-3.71 (m, 6H), 2.33 (s, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.41, 158.19, 135.07, 134.26,

129.75, 119.98, 67.35, 66.90, 47.42, 44.14, 21.06.

N-(4-ethylphenyl)-2-morpholino-2-oxoacetamide (3c): The title compound was synthesized



according to the general procedure and obtained as white solid (45.6 mg, 87%); mp. 112-114 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.19 (s, 1H), 7.50 (d, *J* = 4.0 Hz, 2H), 7.19 (d, *J* = 4.0 Hz, 2H), 4.32 (t, *J* = 4.0 Hz, 2H), 3.79-3.71 (m, 6H), 2.64 (dd, *J* = 12.0 Hz, 4.0 Hz, 2H), 1.23

(t, J = 8.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 160.40, 158.19, 141.53, 134.42, 128.59, 120.08,

67.36, 66.92, 47.44, 44.16, 29.49, 15.71. HRMS (HR-ESI) m/z:  $[M+H]^+$  calcd for  $C_{14}H_{19}N_2O_3$ 263.1395; Found 263.1389.

N-(4-methoxyphenyl)-2-morpholino-2-oxoacetamide (3d):<sup>4</sup> The title compound was



synthesized according to the general procedure and obtained as white solid (48.1 mg, 91%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  9.19 (s, 1H), 7.50 (d, *J* = 8.0 Hz, 2H), 6.88 (d, *J* = 8.0 Hz, 2H), 4.30 (t, *J* = 4.0 Hz, 2H), 3.79 (s, 3H), 3.76-3.71 (m, 6H); <sup>13</sup>C-NMR (100 MHz,

 $\mathsf{CDCl}_3) \ \delta \ 160.80, \ 158.42, \ 157.42, \ 130.27, \ 121.94, \ 114.70, \ 67.66, \ 67.21, \ 55.91, \ 47.73, \ 44.43.$ 

N-(4-fluorophenyl)-2-morpholino-2-oxoacetamide (3e): The title compound was synthesized



according to the general procedure and obtained as white solid (42.3 mg, 84%); mp. 132-134 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.30 (s, 1H), 7.56 (dq, *J* = 8.0 Hz, 4.0 Hz, 2H), 7.07-7.00 (m, 2H), 4.28 (t, *J* = 4.0 Hz, 2H), 3.77-3.69 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  161.0 (d, *J*<sub>C-F</sub> =

243.3 Hz), 160.0, 158.1, 132.7, 121.6, 115.9 (d,  $J_{C-F}$  = 22.4 Hz), 67.1, 66.7, 47.2, 44.0; <sup>19</sup>F{1H} NMR (376MHz, CDCl<sub>3</sub>)  $\delta$  -116.4; HRMS (HR-EI) m/z: [M<sup>+</sup>] C<sub>12</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub>calcd for 252.0910; Found 252.0916.

N-(4-chlorophenyl)-2-morpholino-2-oxoacetamide (3f): The title compound was synthesized



according to the general procedure and obtained as white solid (41.9 mg, 78%); mp. 136-138 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.29 (s, 1H), 7.55 (td, *J* = 8.0 Hz, 4.0 Hz, 2H), 7.32 (td, *J* = 8.0 Hz, 4.0 Hz, 2H), 4.31 (t, *J* = 8.0 Hz, 2H), 3.77-3.72 (m, 6H); <sup>13</sup>C-NMR (100 MHz,

CDCl<sub>3</sub>)  $\delta$  160.40, 158.68, 135.84, 130.88, 129.78, 121.63, 67.77, 67.34, 47.88, 44.70. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd for C<sub>12</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>3</sub> 268.0615; Found 268.0611.

N-(4-bromophenyl)-2-morpholino-2-oxoacetamide (3g): <sup>5</sup> The title compound was synthesized



according to the general procedure and obtained as white solid (49.5 mg, 79%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.31 (s, 1H), 7.52-7.46

(m, 4H), 4.30 (t, *J* = 4.0 Hz, 2H), 3.78-3.72 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 160.40, 158.69, 136.34, 132.72, 121.94, 118.53, 67.76, 67.33, 47.87, 44.68.

2-morpholino-N-(4-nitrophenyl)-2-oxoacetamide (3h): <sup>6</sup> The title compound was synthesized



according to the general procedure and obtained as pale yellow solid (19.5 mg, 35%); mp. 201-203 °C; <sup>1</sup>H-NMR (600 Hz, DMSO- $d_6$ )  $\delta$  11.40 (s, 1H), 8.26 (d, *J* = 18.0 Hz, 2H), 7.91 (d, *J* = 18.0 Hz, 2H), 3.66 (t, *J* = 6.0 Hz, 2H), 3.62 (t, *J* = 6.0 Hz, 2H), 3.58-3.52 (m, 4H);

<sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>) δ 159.03, 158.22, 144.24, 142.21, 125.08, 119.31, 67.10, 66.70, 47.29, 44.26.

N-(2-iodophenyl)-2-morpholino-2-oxoacetamide (3i): The title compound was synthesized



according to the general procedure and obtained as brown solid (28.8 mg, 40%); mp. 125-127 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  8.19 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.40-7.32 (m, 2H), 6.95-6.91 (m, 1H), 3.63 (t, J = 8.0 Hz, 4H), 3.43 (t, J = 8.0 Hz, 4H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  155.24,

140.89, 138.59, 128.55, 127.34, 126.82, 98.25, 66.02, 54.88, 44.30. MASS HRMS (ESI) m/z: [M+H]  $^+$  calcd for C<sub>13</sub>H<sub>14</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 361.0049; Found 361.0062

**2-morpholino-2-oxo-N-(4-(trifluoromethyl)phenyl)acetamide (3j):** The title compound was synthesized according to the general procedure and obtained as white solid (28.4mg, 47%); mp. 152-154 °C; <sup>1</sup>H-NMR (400 Hz, DMSO-*d*<sub>6</sub>)  $\delta$  7.58 (s,1H), 7.47(t, *J* = 8.0 Hz, 1H), 7.11 (t, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 4.0 Hz, 1H), 3.62-3.33 (m, 8H); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  161.4, 153.3,

147.3, 133.4, 126.7 (d,  $J_{C-F}$  = 38.9 Hz), 126.6, 122.8 (d,  $J_{C-F}$  = 75.3 Hz), 122.1 (d,  $J_{C-F}$  = 217.9 Hz), 119.8, 66.3, 66.0, 46.0, 41.3; <sup>19</sup>F{1H} NMR (376MHz, CDCl<sub>3</sub>)  $\delta$  -59.5; MASS HRMS (ESI) m/z: [M-H] calcd for C<sub>13</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub> 301.0800; Found 301.0500.



synthesized according to the general procedure and obtained as white solid (51.2mg, 87%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.45 (s, 1H), 8.18 (d, *J* = 4.0 Hz, 1H), 6.47-6.43 (m, 2H), 4.25 (t, *J* = 8.0 Hz, 2H), 3.84 (s, 3H), 3.77 (s, 3H), 3.74-3.69 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)

δ 160.68, 157.86,157.42,150.11, 120.52, 120.15, 103.82, 98.83, 67.36, 66.91, 55.87, 55.65, 47.33, 43.97.

**N-(2,4-dimethoxyphenyl)-2-morpholino-2-oxoacetamide (3k):**<sup>7</sup> The title compound was

N-mesityl-2-morpholino-2-oxoacetamide (3I): The title compound was synthesized according to



the general procedure and obtained as white solid (17.6 mg, 32%); mp. 166-168 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.57 (s, 1H), 6.91(s, 2H), 4.24 (t, *J* = 8.0 Hz, 2H), 3.80-3.71 (m, 6H), 2.27 (s, 3H) 2.19 (s, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.62, 159.31, 137.60, 134.4, 129.96, 129.15,

67.35, 66.89, 47.31, 43.66, 21.06, 18.44. HRMS (EI) m/z:  $[M+H^+]$  calcd for  $C_{15}H_{21}N_2O_3$  277.1552; Found 277.1540.

N-(4-chloro-3-nitrophenyl)-2-morpholino-2-oxoacetamide (3m): The title compound was



synthesized according to the general procedure and obtained as white solid (18.1 mg, 29%); mp. 184-186 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  11.36 (s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 7.87 (dd, J = 8.0 Hz, 4.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 3.65 (t, J = 8.0 Hz, 2H), 3.61

(t, J = 8.0 Hz, 2H), 3.56 (t, J = 4.0 Hz, 4H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158. 94, 158.25, 148.10, 136.23, 132.27, 123.78, 122.47, 116.43, 67.12, 66.72, 47.31, 44.30. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd for C<sub>12</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>5</sub> 313.0465; Found 313.0464.

N-benzyl-2-morpholino-2-oxoacetamide (3n): The title compound was synthesized according to



the general procedure and obtained as yellow semi solid (32.7 mg, 66%); <sup>1</sup>H-NMR (600 Hz, DMSO- $d_6$ )  $\delta$  9.22 (t, *J* = 18.0 Hz, 1H), 7.36-7.31 (m, 2H), 7.28-7.23 (m, 3H), 4.33 (d, *J* = 6.0 Hz, 2H), 3.61-3.35 (m, 4H), 3.50-3.45 (m, 4H); <sup>13</sup>C-NMR (151 MHz, DMSO- $d_6$ )  $\delta$  163.34, 163.11,

138.60, 128.48, 127.38, 127.11, 66.22, 66.87, 46.13, 41.77, 41.39; HRMS (HR-ESI) m/z: [M+Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>Na 271.1059; Found 271.1045.

2-morpholino-2-oxo-N-(quinolin-3-yl)acetamide (3o): The title compound was synthesized



according to the general procedure and obtained as white solid (30.2 mg, 53%); mp. 157-159 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.86 (s, 1H), 8.94 (s, 1H), 8.82 (s, 1H), 8.09 (t, *J* = 8.0 Hz, 1H), 7.82 (d, *J* = 8.0 Hz, 1H), 7.70-7.65 (m, 1H), 7.57 (t, *J* = 8.0 Hz, 1H), 4.30 (t, *J* = 4.0 Hz, 1H), 4.30 (t,

Hz, 2H), 3.80-3.75 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 159.90, 159.28, 145.19, 143.84, 130.84, 129.37, 128.94, 128.27, 128.13, 127.95, 124.88, 124.88, 67.43, 67.03, 47.59. HRMS (HR-ESI) m/z: [M+H] <sup>+</sup> calcd for C<sub>15</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub> 286.1191; Found 286.1192.

N-(benzo[d]thiazol-2-yl)-2-morpholino-2-oxoacetamide (3p): The title compound was



synthesized according to the general procedure and obtained as white solid (22.1 mg, 38%); mp. 171-172 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  7.86-7.83 (m, 2H), 7.49-7.456 (m, 1H), 7.337-7.33 (m, 1H), 4.32 (t, *J* = 4.0 Hz, 2H), 3.80-3.77 (m, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.30, 157.78, 156.17, 148.50, 132.18, 126.49, 124.49, 121.60,

121.40, 67.08, 66.71, 47.10, 44.19. HRMS (HR-ESI) m/z:  $[M+Na]^+$  calcd for  $C_{13}H_{13}N_3O_3SNa$  314.0576; Found 314.0572.

N<sup>1</sup>,N<sup>1</sup>-dimethyl-N<sup>2</sup>-phenyloxalamide (5a): The title compound was synthesized according to the



general procedure and obtained as white solid (31.1 mg, 81%); mp. 97-99 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.26 (s, 1H), 7.60 (d, J = 4.0 Hz, 2H), 7.36 (t, J = 8.0 Hz, 2H), 7.18-7.14 (m,1H), 3.51 (s, 3H), 3.09 (s, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.06, 158.96, 137.39, 129.66, 125.57, 120.36, 39.38,

38.41. HRMS (HR-ESI) m/z: [M+Na] <sup>+</sup> calcd for C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>Na 215.0797; Found 215.0798.

N<sup>1</sup>,N<sup>1</sup>-diethyl-N<sup>2</sup>-phenyloxalamide (5b): <sup>5</sup> The title compound was synthesized according to



the general procedure and obtained as brown solid (28.6 mg, 65%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.40 (s, 1H), 7.61-7.58 (m, 2H), 7.36-7.31 (m, 2H), 7.15-7.11 (m, 1H), 3.83 (q, *J* = 8.0 Hz, 2H), 3.45 (q, *J* = 8.0 Hz, 2H), 1.31 (t, *J* = 4.0 Hz, 3H), 1.21 (t, *J* = 4.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 

161.30, 158.77, 137.03, 129.04, 124.90, 119.92, 43.70, 42.76, 14.77, 12.44.

2-oxo-N-phenyl-2-(pyrrolidin-1-yl) acetamide (5c):<sup>3</sup> The title compound was synthesized



according to the general procedure and obtained as brown solid (24.0 mg, 55%); mp. 137-139 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.50 (S, 1H), 7.63-7.61 (m, 2H), 7.35 (t, *J* = 8.0 Hz, 2H), 7.17-7.13 (m, 1H), 4.08 (t, *J* = 8.0 Hz, 2H), 3.61 (t, *J* = 8.0 Hz, 2H), 1.99 (q, *J* = 12.0 Hz, 4.0 Hz, 2H), 1.87 (q, *J* =

12.0 Hz, 4.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 159.04, 158.13, 136.92, 129.11, 124.92, 119.74, 49.01, 48.38, 26.95, 23.44.

2-oxo-N-phenyl-2-(piperidin-1-yl) acetamide (5d):<sup>4</sup> The title compound was synthesized



according to the general procedure and obtained as brown solid (34.3mg, 74%); mp. 165-167 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.20 (s, 1H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.35 (t, *J* = 8.0 Hz, 2H), 7.17-7.13 (m, 1H), 4.07 (t, *J* = 8.0 Hz, 2H), 3.64 (t, *J* = 4.0 Hz, 2H), 1.69-1.63 (m, 6H); <sup>13</sup>C-NMR (100

MHz, CDCl<sub>3</sub>) δ 160.86, 159.26, 137.13, 129.20, 125.09, 120.00, 47.86, 45.01, 26.97, 25.93, 24.59.

N1-methyl-N1,N2-diphenyloxalamide (5e): The title compound was synthesized according to



the general procedure and obtained as pale yellow semi solid (40.1mg, 79%); 9.19 (s, 1H), 7.47 (d, *J* = 4.0 Hz, 2H), 7.42-7.39 (m, 2H), 7.36-7.32 (m, 1H), 7.27 (t, *J* = 8.0 Hz, 2H), 7.23-7.21 (m, 2H), 7.10 (t, *J* = 4.0 Hz, 1H), 3.40 (s, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ

164.26, 161.73, 142.06, 137.65, 129.30, 128.83, 127.65, 126.15, 124.16, 119.62, 35.91. HRMS (HR-ESI) m/z: [M+Na] <sup>+</sup> calcd for C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>Na 277.0953; Found 277.0944.

N<sup>1</sup>-butyl-N<sup>2</sup>-phenyloxalamide (5f): <sup>8</sup> The title compound was synthesized according to the



general procedure and obtained as brown sticky solid (27.3 mg, 62%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  8.35 (s, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.19 (t, J = 8.0 Hz, 2H), 6.88-6.84 (m, 1H), 6.08 (t, J = 4.0 Hz, 1H), 3.06 (dd, J = 12.0 Hz, 4.0 Hz, 2H), 1.42 – 1.38 (m, 2H), 1.33-1.29 (m,

2H), 0.89 (t, *J* = 4.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 156.67, 152.18, 138.57, 129.38, 124.01, 121.39, 40.29, 32.25, 20.17, 13.90.

N<sup>1</sup>-(tert-butyl)-N<sup>2</sup>-phenyloxalamide (5g): <sup>9</sup> The title compound was synthesized according to



the general procedure and obtained as white semi solid (34.4mg, 78%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  8.20 (s, 1H), 7.33 (dd, J = 12.0 Hz, 4.0 Hz, 2H), 7.19 (t, J = 8.0 Hz, 2H), 6.88-6.84 (m, 1H), 1.28 (s, 9H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.10, 155.82, 139.95, 129.62, 123.41, 120.68,

51.41, 30.30.

N<sup>1</sup>-phenethyl-N<sup>2</sup>-phenyloxalamide (5h): The title compound was synthesized according to the



general procedure and obtained as white gum solid (32.7mg, 61%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  7.38-7.06 (m, 12H), 3.49 (t, J = 8.0 Hz, 2H), 2.82 (t, J = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.27, 156.40, 139.21, 138.32, 129.66, 129.14, 128.96,

126.82, 124.62, 122.00, 41.87, 36.40. HRMS (ESI) m/z: [M+H] <sup>+</sup> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> 261.1290; Found 261.1284.

N<sup>1</sup>-phenyl-N<sup>2</sup>-(p-tolyl)oxalamide (5i): The title compound was synthesized according to the



general procedure and obtained as brown sticky solid (33.1 mg, 65%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>) δ 8.65 (dd, *J* = 32.0 Hz, 12.0 Hz, 1H), 8.37 (d, *J* = 4.0 Hz, 1H), 7.54 (d, , *J* = 4.0 Hz, 1H), 7.43-7.39 (m, 1H), 7.36 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.23-7.20 (m, 1H), 7.18-7.07 (m, 4H), 6.98 (d, *J* = 12.0 Hz, 1H), 2.33 (m, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)

 $\delta\,162.44,\,159.00,\,130.41,\,129.99,\,129.94,\,129.75,\,129.28,\,125.54,\,125.01,\,121.87,\,120.15,\,120.08,\,120.12,\,12$ 

119.45, 119.08, 20.95. HRMS (ESI) m/z: [M+Na]  $^+$  calcd for C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>Na 277.0953; Found 277.0964.

N<sup>1</sup>, N<sup>2</sup>-di-p-tolyloxalamide (5j): <sup>10</sup> The title compound was synthesized according to the general



procedure and obtained as brown sticky solid (32.7mg, 61%); mp. 255-257 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  8.52 (s, 2H), 7.32 (d, *J* = 8.0 Hz, 4H), 7.07 (d, *J* = 8.0 Hz, 4H), 2.24 (s, 6H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  153.02, 137.63, 130.85, 129.51, 118.59,

118.58, 20.70.

N<sup>1</sup>,N<sup>1</sup>-dimethyl-N<sup>2</sup>-phenyloxalamide (5a): The title compound was synthesized according to the



general procedure and obtained as white solid (33.8mg, 88%); mp. 93-95 °C; <sup>1</sup>H-NMR (600 Hz, CDCl<sub>3</sub>)  $\delta$  9.26 (s, 1H), 7.61-7.59 (m, 2H), 7.35 (t, *J* = 12.0 Hz, 2H), 7.17-7.14 (m, 1H), 3.51 (s, 3H), 3.09 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  161.67, 158.56, 137.00, 129.24, 125.15, 119.97, 38.97, 38.00. HRMS (HR-ESI) m/z: [M+Na] <sup>+</sup> calcd for C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>Na 215.0797; Found

215.0798.

N<sup>1</sup>,N<sup>1</sup>-dimethyl-N<sup>2</sup>-(p-tolyl)oxalamide (5k): <sup>11</sup> The title compound was synthesized according to



the general procedure and obtained as pale yellow solid (32.68 mg, 79%); <sup>1</sup>H-NMR (600 Hz, CDCl<sub>3</sub>)  $\delta$  9.18 (s, 1H), 7.53-7.50 (m, 2H), 6.90-6.88 (m, 2H), 3.80(s, 3H), 3.51 (s, 3H), 3.08 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  161.87, 158.52, 134.80, 134.47, 129.69, 119.96, 38.90, 37.86,

21.04.

N<sup>1</sup>-(4-methoxyphenyl)-N<sup>2</sup>, N<sup>2</sup>-dimethyloxalamide (51): The title compound was synthesized



according to the general procedure and obtained as pale yellow solid (32.0 mg, 72%); mp. 113-115 °C; <sup>1</sup>H-NMR (600 Hz, CDCl<sub>3</sub>)  $\delta$  9.18 (s, 1H), 7.53-7.50 (m, 2H), 6.90-6.88 (m, 2H), 3.80 (s, 3H), 3.51 (s, 3H), 3.08 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  162.07, 158.59, 157.22, 130.40,

121.79, 114.61, 55.84, 39.15, 38.14. HRMS (HR-ESI) m/z:  $[M+Na]^+$  calcd for  $C_{11}H_{14}N_2O_3Na$  245.0902; Found 245.0902.

N<sup>1</sup>-(4-chlorophenyl)-N<sup>2</sup>,N<sup>2</sup>-dimethyloxalamide (5m): The title compound was synthesized



according to the general procedure and obtained as pale yellow solid (18.6 mg, 41%); mp. 131-133 °C; <sup>1</sup>H-NMR (600 Hz, CDCl<sub>3</sub>)  $\delta$  9.33 (s, 1H), 7.57-7.55 (m, 2H), 7.33-7.30 (m, 2H), 3.51 (s, 3H), 3.09 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  161.56, 158.71, 135.82, 130.42, 129.51,

121.37, 39.18, 38.29. HRMS (HR-ESI) m/z: [M+Na] <sup>+</sup> calcd for C<sub>10</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub>Na 249.0407; Found 249.0407.

 $N^{1}$ -(4-bromophenyl)- $N^{2}$ , $N^{2}$ -dimethyloxalamide (5n): <sup>5</sup> The title compound was synthesized



according to the general procedure and obtained as pale yellow solid (32.5 mg, 60%); <sup>1</sup>H-NMR (600 Hz, CDCl<sub>3</sub>)  $\delta$  9.31 (s, 1H), 7.52-7.45 (m, 4H), 3.51 (s, 3H), 3.09 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  161.51, 158.68, 136.31, 132.47, 121.67, 118.08, 39.19, 38.33.

**N<sup>1</sup>-phenyloxalamide** (50):<sup>3</sup> The title compound was synthesized according to the general procedure and obtained as white solid (21.0 mg, 64%); mp. 102-104 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.56 (s, 1H), 8.30 (bs, 1H), 7.98 (bs, 1H), 7.81 (d, *J*= 9.24 Hz), 7.34 (t, *J*= 8.24), 7.12 (t, *J*= 7.4 Hz); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  162.7, 159.4, 138.2, 129.2, 124.9, 120.7.

 $N^1$ , $N^1$ -diethyl- $N^2$ -(p-tolyl)oxalamide (5p): <sup>5</sup> The title compound was synthesized according to



the general procedure and obtained as brown semi-solid (33.3 mg, 71%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>) δ 10.57 (s, 1H), 7.53 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H), 2.26 (s, 3H), 1.34-1.22 (m, 3H), 1.17-1.10 (m, 7H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 161.70, 158.99, 135.19, 134.99,

130.15, 120.39, 44.31, 43.51, 21.51, 15.39, 13.03.

2-bromo-2,2-dichloro-N-phenylacetamide (6a): The title compound was synthesized according



to the general procedure and obtained as white solid (49.8 mg, 88%); mp. 102-104 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.74 (s, 1H), 7.67-7.64 (m, 2H), 7.41 (t, *J* = 8.0 Hz, 2H), 7.43-7.19 (m, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.14, 136.59, 129.92, 126.61, 120.89, 75.83. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd for

C<sub>8</sub>H<sub>6</sub>BrCl<sub>2</sub>NO 280.9010; Found 280.9005.

2-bromo-2,2-dichloro-N-(p-tolyl) acetamide (6b): The title compound was synthesized according



to the general procedure and obtained as brown solid (41.5 mg, 70%); mp. 115-117 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>) δ 8.31 (s, 1H), 7.45 (d, *J* = 8.0 Hz, 2H), 7.20 (d, *J* = 8.0 Hz, 2H), 2.36 (s, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 159.32, 135.70, 133.22, 129.64, 120.14, 75.15, 20.78. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd

C<sub>9</sub>H<sub>8</sub>BrCl<sub>2</sub>NO for 294.9166; Found 294.9160.

2-bromo-2,2-dichloro-N-(4-ethylphenyl)acetamide (6c): The title compound was synthesized



according to the general procedure and obtained as brown solid (32.9 mg, 53%); mp. 119-121 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.32 (s, 1H), 7.48 (d, *J* = 8.0 Hz, 2H), 7.23 (d, *J* = 8.0 Hz, 2H), 2.65 (q, *J* = 16.0 Hz, 8.0 Hz, 2H), 1.24 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.65,

142.42, 133.72, 128.80, 120.54, 75.49, 28.51, 15.71. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd for  $C_{10}H_{10}BrCl_2NO$  308.9323; Found 308.9319.

2-bromo-2,2-dichloro-N-(4-methoxyphenyl)acetamide (6d): The title compound was



synthesized according to the general procedure and obtained as white solid (41.9 mg, 67%); mp. 109-111 °C; <sup>1</sup>H-NMR (600 Hz, DMSO- $d_6$ )  $\delta$  7.54 (d, J = 12.0 Hz, 2H), 6.96 (d, J = 12.0 Hz, 2H), 3.76 (s, 3H); <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  159.76, 157.81, 129.08, 122.29, 114.61, 55.69. HRMS

(HR-EI) m/z:  $[M^+]$  calcd C<sub>9</sub>H<sub>8</sub>BrCl<sub>2</sub>NO<sub>2</sub>for 310.9115; Found 310.9124.





according to the general procedure and obtained as brown solid (36.7mg, 61%); mp. 102-104 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.41 (s, 1H), 7.54 (dq, *J* = 8.0 Hz, 4.0 Hz, 2H), 7.08 (t, *J* = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  161.7 (d, *J*<sub>C-F</sub> = 175.8 Hz), 159.2, 132.1, 122.6 (d, *J*<sub>C-F</sub> = 8.2 Hz), 116.3 (d, *J*<sub>C-F</sub>

= 22.7 Hz), 75.1; <sup>19</sup>F{1H} NMR (376MHz, CDCl<sub>3</sub>) δ-115.2; HRMS (HR-EI) m/z: [M<sup>+</sup>] C<sub>8</sub>H<sub>5</sub>BrCl<sub>2</sub>FNO calcd for 298.8916; Found 298.8910.

2-bromo-2,2-dichloro-N-(4-chlorophenyl)acetamide (6f): The title compound was synthesized



according to the general procedure and obtained as white solid (43.1 mg, 68%); mp. 134-136 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.86 (s, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.59, 134.49, 131.27, 129.37, 121.60, 74.88. HRMS (HR-EI) m/z: [M<sup>+</sup>]

 $C_8H_5BrCl_3NO$  calcd for 314.8620; Found 314.8620.

2-bromo-N-(4-bromophenyl)-2,2-dichloroacetamide (6g): The title compound was synthesized



according to the general procedure and obtained as white solid (70.9 mg, 98%); mp. 131-133 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.85 (s, 1H), 7.65-7.57 (m, 4H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )  $\delta$  160.91, 137.11, 132.08, 123.72, 117.68, 75.31. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd

C<sub>8</sub>H<sub>5</sub>Br<sub>2</sub>Cl<sub>2</sub>NO for 358.8115; Found 358.8107.

2-bromo-2,2-dichloro-N-(4-nitrophenyl)acetamide (6h): The title compound was synthesized



according to the general procedure and obtained as yellow solid (45.2 mg, 69%); mp. 136-138 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.64 (s, 1H), 8.32-8.28 (m, 2H), 7.83-7.79 (m, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.98, 145.17, 141.84, 125.43, 120.30, 74.61. HRMS (HR-EI) m/z: [M<sup>+</sup>]

 $C_8H_5BrCl_2N_2O_3$  calcd for 325.8861; Found 325.8862.





synthesized according to the general procedure and obtained as yellow liquid (60.3 mg, 86%); <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.81 (s, 1H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.70-7.63 (m, 2H), 7.36-7.34(m, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.0, 133.2 (d, *J*<sub>C-F</sub> = 33.0 Hz), 126.3 (q, *J*<sub>C-F</sub> = 41.2 Hz), 126.0, 125.1, 124.0,

122.4 (d,  $J_{C-F}$  = 166.9 Hz), 121.1, 74.7; <sup>19</sup>F{1H} NMR (376MHz, CDCl<sub>3</sub>) δ -60.5; HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd C<sub>9</sub>H<sub>5</sub>BrCl<sub>2</sub>F<sub>3</sub>NO for 348.8884; Found 348.8838.

2-bromo-2,2-dichloro-N-(3-(trifluoromethyl) phenyl) acetamide (6j): The title compound was



synthesized according to the general procedure and obtained as white solid (66.6 mg, 95%); mp. 138-140 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.47 (s,1H), 7.70 (dd, *J* = 24.0Hz, 18.0Hz, 4H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.7, 139.0, 128.0, 127.7, 126.6 (q, *J*<sub>C-F</sub> = 75.7 Hz), 125.1 (d, *J*<sub>C-F</sub> = 138.7

Hz), 122.4 (d,  $J_{C-F}$  = 229.0 Hz), 74.7; <sup>19</sup>F{1H} NMR (376MHz, CDCl<sub>3</sub>)  $\delta$  -62.3; HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd C<sub>9</sub>H<sub>5</sub>BrCl<sub>2</sub>F<sub>3</sub>NO for 348.8884; Found 348.8885.

2-bromo-2,2-dichloro-N-(2,4-dimethoxyphenyl)acetamide (6k): The title compound was



synthesized according to the general procedure and obtained as black semi solid (21.9 mg, 32%); <sup>1</sup>H-NMR (600 Hz, DMSO- $d_6$ )  $\delta$  9.81 (s, 1H), 7.33 (d, *J* = 12.0 Hz, 1H), 6.67 (d, *J* = 6.0 Hz, 1H) 6.56 (dd, *J* = 12.0 Hz, 4.0 Hz), 3.81 (s, 3H), 3.78 (s, 3H); <sup>13</sup>C-NMR (151 MHz, DMSO- $d_6$ )  $\delta$  160.63, 158.92, 153.87, 126.03, 117.88, 104.48, 99.13, 74.91, 95.94, 95.37. HRMS (HR-EI)

m/z:  $[M^+]$  calcd  $C_{10}H_{10}BrCl_2NO_3$  for 340.9221; Found 340.9229.

2-bromo-2,2-dichloro-N-mesitylacetamide (6I): The title compound was synthesized according



to the general procedure and obtained as yellow solid (50.0mg, 77%); mp. 142-144 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  7.90 (s, 1H), 6.92 (s, 2H), 2.29 (S, 3H), 2.23 (s, 6H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.74, 138.41, 135.55, 129.52, 75.73, 21.28, 18.20. HRMS (HR-EI) m/z: [M<sup>+</sup>] calcd C<sub>11</sub>H<sub>12</sub>BrCl<sub>2</sub>NO for 322.9479; Found 322.9470.

2-bromo-2,2-dichloro-N-(4-chloro-3-nitrophenyl)acetamide (6m): The title compound was



synthesized according to the general procedure and obtained as white solid (59.4 mg, 82%); mp. 105-107 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  8.59 (s, 1H), 8.23 (d, *J* = 4.0 Hz, 1H), 7.79 (dd, *J* = 8.0 Hz, 4.0 Hz, 1H), 7.59 (d, *J* = 4.0 Hz, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.94, 135.51, 132.57,

124.54, 123.62, 117.23, 74.05. HRMS (HR-EI) m/z: [M<sup>+</sup>] C<sub>8</sub>H<sub>4</sub>BrCl<sub>3</sub>N<sub>2</sub>O<sub>3</sub> calcd for 359.8471; Found 359.8471.

N-benzyl-2-bromo-2,2-dichloroacetamide (6n): The title compound was synthesized according



to the general procedure and obtained as white solid (42.2 mg, 71%); mp. 104-106 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  9.53 (s, 1H), 7.36-7.24 (m, 5H), 4.38 (d, *J* = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  162.41, 136.48, 129.14, 128.31, 127.91, 75.16, 45.60. HRMS (EI) m/z: [M<sup>+</sup>] C<sub>9</sub>H<sub>8</sub>BrCl<sub>2</sub>NO

calcd for 294.9166; Found 294.9166.

N-(2-(1H-indol-3-yl)ethyl)-2-bromo-2,2-dichloroacetamide (6o): The title compound was



synthesized according to the general procedure and obtained as light brown semi solid (22.40 mg, 32%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  10.83 (s, 1H), 9.06 (t, J = 8.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.17 (s, 1H), 7.07 (t, J = 8.0 Hz, 1H), 6.99 (t, J = 8.0 Hz)

Hz, 1H), 3.50-3.43 (m, 2H), 2.92 (t, *J* = 8.0 Hz, 2H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 162.68, 136.91, 127.46, 122.92, 122.77, 120.19, 119.08, 112.50, 111.81, 75.73, 42.14, 25.12. HRMS (HR-EI) m/z: [M<sup>+</sup>] C<sub>12</sub>H<sub>11</sub>BrCl<sub>2</sub>N<sub>2</sub>O calcd for 347.9432; Found 347.9440.

N-(1-benzylpyrrolidin-3-yl)-2-bromo-2,2-dichloroacetamide (6p): The title compound was



synthesized according to the general procedure and obtained as brown solid (56.3 mg, 77%); mp. 168-170 °C; <sup>1</sup>H-NMR (400 Hz, CDCl<sub>3</sub>)  $\delta$  9.09 (s, 1H), 7.57 (s, 2H), 7.44-7.38 (m, 3H), 4.92 (s, 1H), 4.35-4.28

(m,2H), 3.78 (s, 1H), 3.65-3.62 (m, 1H), 3.27 (s, 1H), 3.00 (s, 1H), 2.63-2.61 (m, 1H), 2.38-2.36 (m, 1H); <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) δ 163.02, 130.61, 129.71, 128.90, 128.53, 74.47, 58.15, 52.55,

48.83, 34.42, 31.74. HRMS (HR-ESI) m/z: [M+H] <sup>+</sup> calcd for C<sub>13</sub>H<sub>16</sub>BrCl<sub>2</sub>N<sub>2</sub> 364.9823; Found 364.9812.

2-bromo-2,2-dichloro-N-(quinolin-3-yl) acetamide (6q): The title compound was synthesized



according to the general procedure and obtained as pale-yellow solid (41.4 mg, 62%); mp. 109-111 °C; <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  11.25 (s, 1H), 9.09 (d, J = 4.0 Hz, 1H), 8.67 (d, J = 4.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 2H), 7.76-7.72 (m, 1H), 7.65-7.61 (m, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO-

 $d_6$ )  $\delta$  161.16, 145.64, 145.00, 131.06, 128.95, 128.57, 128.06, 127.34, 127.28, 125.72, 74.54; HRMS (EI) m/z: [M<sup>+</sup>] C<sub>12</sub>H<sub>13</sub>FN<sub>2</sub>O<sub>3</sub> calcd for 252.0910; Found 252.0916.



*N*-phenylmorpholine-4-carboxamide (7a): <sup>12</sup> The title compound was synthesized according to the general procedure and obtained as white solid (25.5 mg, 62%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  8.50 (s, 1H), 7.46-7.44 (m, 2H), 7.25-7.21 (m, 2H), 6.96-6.91 (m, 1H), 3.61 (t, *J* = 8.0 Hz, 4H), 3.42

(t, *J* = 4.0 Hz, 4 Hz); <sup>13</sup>C-NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 155.17, 140.35, 128.28, 121.80, 119.64, 119.63, 119.62, 119.60, 119.59, 66.99, 44.16.



indoline-2,3-dione (3aa): <sup>2</sup> The title compound was synthesized according to the general procedure and obtained as orange solid (18.2 mg, 62%); <sup>1</sup>H-NMR (400 Hz, DMSO- $d_6$ )  $\delta$  11.03 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.49 (d, J = 4.0 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.90 (d, J = 4.0 Hz, 1H); <sup>13</sup>C-NMR (100 MHz, DMSO- $d_6$ )

δ 184.38, 159.36, 150.71, 138.37, 124.69, 122.76, 117.82, 112.20.

#### 17. References:

(1) D. M. Heard and A. Lennox, J. Org. Lett. 2021, 23, 3368-3372.

(2) Y. Zi, Z.-J. Cai, S.-Y. Wang and S.-J. Ji, Org. Lett. 2014, 16, 3094-3097.

(3) A. Nagaki, Y. Takahashi and J. i. Yoshida, Angew. Chem., Int. Ed. Engl. 2016, 55, 5347-5347.

(4) Z. Zhan, X. Cheng, X. Ma, J. Li, L. Hai and Y. Wu, *Tetrahedron Lett.* 2015, **71**, 6928-6934.

(5) X. Zhuang, L. Ling, Y. Wang, B. Li, B. Sun, W. Su and C. Jin, Org. Lett. 2022, 24, 1668-1672.

(6) H. Gross and G. Zinner, Aminen. Chem. Ber. 1973, 106, 2315-2323.

(7) J. J. Mason, T. Janosik and J. Bergman, Synthesis. 2009, 3642-3648.

(8) N. Kambe, T. Inoue, T. Takeda, S.-i. Fujiwara and N. Sonoda, J. Am. Chem. Soc. 2006, 128, 12650-12651.

(9) C. Zhang, Y. Zhao, B. Li, H. Song, S. Xu and B. Wang, Dalton Trans. 2009, 26, 5182-5189.

(10) B. Zhu, W. Xiong, X. Tan, W. Wu and H. Jiang, *Tetrahedron Lett.* 2022, **109**, 154140.

(11) P. Wu, W. Huang, T.-J. Cheng, H.-X. Lin, H. Xu and H.-X. Dai, Org. Lett. 2020, 22, 5051-5056.

(12) S.-Y. Moon, U. B. Kim, D.-B. Sung and W.-S. Kim, J. Org. Chem. 2015, 80, 1856-1865.

# **Proton and Carbon Spectrum**







<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz







 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz



16.1808

28.9478



67.5006



<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz






 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- 67.0614



<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz





 $^{13}\text{C}\left\{ ^{1}H\right\}$  NMR spectrum

Solvent: CDCl<sub>3</sub>

Spectrometer Frequency: 100 MHz







- 6.0632







 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz



- 66.7441







<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz





<sup>13</sup>C {<sup>1</sup>H} NMR spectrum
 Solvent: DMSO-d<sub>6</sub>
 Spectrometer Frequency: 100 MHz

- 67.5336













 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz



- 65.9778









 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz















<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: DMSO-d<sub>6</sub>
Spectrometer Frequency: 100 MHz





- 67.0673



<sup>1</sup>H NMR spectrum

Solvent: CDCl<sub>3</sub>

**Spectrometer Frequency: 400 MHz** 

- 6.0358





1.00년 1.01년 1.02년 0.99년 2.00H 2.00H 1.00-1 1.00-1 0.96-≖ ຽ່50 f1 (ppm) 4.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0



66.4574

40.5309



- 24.7556

 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz















67.0537 66.5951



 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- 9.1989













 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz



- 21.0614









9.1937











---- 15.7135

 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

















 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

















67.1448
66.7056

- 47.2482 - 44.0000

 $\begin{bmatrix} H & O \\ H & N \\ O & O \end{bmatrix}$ 

<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 100 MHz

- 160.9933 - 160.0371 - 158.5642 - 158.1022



## $^{19}\text{F}\{^{1}H\}$ NMR spectrum Solvent:CDCl\_{3} Spectrometer Frequency: 376 MHz



													-   -				
200	180	160	140	120	100	80	60	40	20 f	<sup>S ტ2</sup> -10 f1 (ppm)	-30	-50	-70	-90	-120	-150	-180















 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz









9.3135









----- 47.8738 ---- 44.6822

 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz















 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 151 MHz



- 47.2883 - 44.2559















162.1440 161.6694	139.1034 138.0219	128.8649 128.3850 126.9992	96.2517	66.2986 65.8033	46.2936 41.5955
$\mathbf{Y}$	57	$\langle \rangle$		$\mathbf{Y}$	

<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: DMSO-d<sub>6</sub>
Spectrometer Frequency: 100 MHz



160-17-18-18-19-19-19-19-19-19-19-19-19-19-19-19-19-	and the state of the	9075-0075-0075-007-007-007-007-007-007-00		1491/07142/Laten/Indon/Aques/Patter				12	 ugunan jaran ya jaran karana	044715481-01147-0415-11 <sup>1-</sup> 01-11-11					######################################	an Tanan San San San San San San San San San	NEXT BILLEN OF A DESCRIPTION	10-10-10-10-10-10-10-10-10-10-10-10-10-1
	180	170	160	150	140	130	120	110	 90	80	70	60	50	40	30	20	10	









66.2906
66.0352

— 46.0353 — 41.3355



<sup>13</sup>C {<sup>1</sup>H} NMR spectrum
 Solvent: DMSO-d<sub>6</sub>
 Spectrometer Frequency: 100 MHz


<sup>19</sup>F{<sup>1</sup>H} NMR spectrum Solvent: DMSO-d<sub>6</sub>
Spectrometer Frequency: 376 MHz



- -59.5025

							1 1 1 1						$ $ $ $ $ $ $ $						
200	180	160	140	120	100	80	60	40	20	57გ f1 (ppm	-10 1)	-30	-50	-70	-90	-110	-140	-170	



<a>8.1939</a><a>8.1724</a>











O

H

0

3k

0

 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

















 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

















 $\frac{9.2377}{0.2229}$ 















9.8610

ł









67.4349 67.0322



Ο

Н

30

ö

<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: CDCl<sub>3</sub>
Spectrometer Frequency: 100 MHz













67.0780
66.7057

----- 47.1029 ---- 44.1859

 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz















 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

~ 39.3777 ~ 38.4120

















 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





















 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- 26.9459 - 23.4409





- 9.1975













∠ 27.1560 → 26.1158 → 24.7798

 $\begin{array}{c}
H \\
H \\
O \\
O \\
5d
\end{array}$ 

 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz









- 3.4092



<sup>13</sup>C {<sup>1</sup>H} NMR spectrum
 Solvent: DMSO-d<sub>6</sub>
 Spectrometer Frequency: 100 MHz

















 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

10.2950	32.2493
4	÷.
	1

- 20.1665 - 13.8969













<sup>13</sup>C {<sup>1</sup>H} NMR spectrum
 Solvent: DMSO-d<sub>6</sub>
 Spectrometer Frequency: 100 MHz



- 51.4089













 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz







2.3365 2.3197 2.3133







 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz







8.5200

<sup>1</sup>H NMR spectrum Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 400 MHz







<sup>13</sup>C {<sup>1</sup>H} NMR spectrum
 Solvent: DMSO-d<sub>6</sub>
 Spectrometer Frequency: 100 MHz











- 3.0908

3.5141



 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 151 MHz










~ 38.9012 ~ 37.8598

21.0406

 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 151 MHz





9.1845

<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 600 MHz







~ 39.1467 ~ 38.1445

 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 151 MHz







- 9.1845

<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 600 MHz

















 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





10.5640



## <sup>1</sup>H NMR spectrum Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 400 MHz







<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: DMSO-d<sub>6</sub>
Spectrometer Frequency: 100 MHz

- 129.1971 - 124.8837 - 120.7227







3.8876 3.8701 3.8525 3.8525 3.8701 3.8701 3.4701 3.4701 3.4523 3.4345 3.4345

1.3359 1.3184 1.3007 1.2339 1.1982



<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz

9.2545





~ 44.3103 ~ 43.5057



5p

 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz







- 75.8324

## $^{13}\text{C}\left\{^{1}H\right\}$ NMR spectrum Solvent: $\text{CDCl}_{3}$ Spectrometer Frequency: 100 MHz

160.1387













 $^{13}\text{C}\left\{ ^{1}H\right\}$  NMR spectrum

Solvent: CDCl<sub>3</sub>

**Spectrometer Frequency: 100 MHz** 

---- 75.1511



H CI CI N Br O 6b





2.6824 2.6634 2.6455 2.6255 √ 1.2554
 1.2364
 1.2174

<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz







- 75.4850

- 28.5063

— 15.7148



Т 5<u>100</u> f1 (ppm) 

<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: CDCl<sub>3</sub>
Spectrometer Frequency: 100 MHz 

<sup>1</sup>H NMR spectrum Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 600 MHz





3.7574













— 75.1101

 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- -115.1855

 $^{19}\text{F}\{^{1}H\}$  NMR spectrum Solvent:CDCl $_{3}$  Spectrometer Frequency: 376 MHz



180	160	140	120	100	80	60	40	20	S&30_10 f1 (ppm)	-30	-50	-70	-90	-120	-150	-180











 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

159.5926





- 74.8786











 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- 75.3099









 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz













133.5199
133.1898
133.1898
126.4546
126.4546
126.4421
126.3494
126.0422
126.0422
125.0780
125.0780
125.0780
122.3652
121.1142
121.1142

--- 74.6841

 $^{13}\text{C}\left\{^{1}H\right\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

159.9785





-60.4560

## $^{19}\text{F}\{^{1}\text{H}\}$ NMR spectrum Solvent:CDCl $_{3}$ Spectrometer Frequency: 376 MHz



							<b>1</b>								$\cdots$		· · · · · · ·		T
200	180	160	140	120	100	80	60	40	20	2439	-20	-40	-60	-80	-100	-130	-160	-190	
										f1 (ppm	)								











159.7002

 $^{13}\text{C}\left\{ ^{1}H\right\}$  NMR spectrum

Solvent: CDCl<sub>3</sub>

Spectrometer Frequency: 100 MHz

--- 74.6786





 $^{19}\text{F}\{^{1}\text{H}\}$  NMR spectrum Solvent:CDCl $_{3}$  Spectrometer Frequency: 376 MHz



	<u> </u>																
200	180	160	140	120	100	80	60	40	20	S162 -10 f1 (ppm)	-30	-50	-70	-90	-120	-150	-180

- -62.2716






<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz









 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz





- 75.7253



<sup>1</sup>H NMR spectrum Solvent: CDCl<sub>3</sub> Spectrometer Frequency: 400 MHz







----- 74.0536

 $^{13}C$   $\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz







<4.3919</li><4.3768</li>

<sup>1</sup>H NMR spectrum Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 400 MHz

9.5296

















~ 112.5043 ~ 111.8141

---- 75.7342

42.1445

H CI CI H CI CI Br

60

 $^{13}C~\{^{1}H\}$  NMR spectrum Solvent:  $\text{CDCl}_{3}$  Spectrometer Frequency: 100 MHz

162.6751















<sup>1</sup>H NMR spectrum Solvent:DMSO-*d*<sub>6</sub> Spectrometer Frequency: 400 MHz

















<sup>13</sup>C {<sup>1</sup>H} NMR spectrum Solvent: DMSO-d<sub>6</sub>
Spectrometer Frequency: 100 MHz



44.1579

65.9851





<sup>1</sup>H NMR spectrum Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 400 MHz







Solvent: DMSO-*d*<sub>6</sub> Spectrometer Frequency: 100 MHz



